scholarly journals 305: Irradiation of cellular blood components with cobalt 60 is very efficient and safe in the prevention of transfusion associated graft versus host disease (TA-GVHD) in the allogeneic transplant setting

2007 ◽  
Vol 13 (2) ◽  
pp. 111
Author(s):  
A. Karduss ◽  
E. Leon ◽  
L. Buitrago ◽  
L.P. Gomez ◽  
J.A. Jimenez ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Blood Components ◽  
Allogeneic Transplant ◽  
Host Disease ◽  
Graft Versus Host

Incidence and Timing of Graft Versus Host Disease (GVHD) After Daratumumab(Dara) Anti CD38 Therapy Post Allogeneic Transplant (alloHCT)for Myeloma

2017 ◽  
Vol 17 (1) ◽  
pp. e71 ◽  
Author(s):  
Amrita Krishnan ◽  
Hari Parameswaran ◽  
Saurabh Chhabra ◽  
Noa Biran ◽  
Tracy Stiller ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Allogeneic Transplant ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide

Blood ◽  
1992 ◽  
Vol 79 (10) ◽  
pp. 2784-2788 ◽  
Author(s):  
JH Essell ◽  
JM Thompson ◽  
GS Harman ◽  
RD Halvorson ◽  
MJ Snyder ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Allogeneic Bone Marrow Transplantation ◽  
Occlusive Disease ◽  
Allogeneic Bone ◽  
Allogeneic Transplant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Gvhd Prophylaxis ◽  
The Mean ◽  
Total Body

The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation. We report 87 patients prepared for allogeneic transplant with busulfan 4 mg/kg/d orally for 4 days, followed by cyclophosphamide 60 mg/kg/d intravenously for 2 days (Bu4Cy2). A marked increase in hepatotoxicity was observed in 20 patients administered CyA/MTX, compared with 67 historical control patients who received CyA/methylprednisolone (CyA/MP) for GVHD prophylaxis with all other treatment and support variables remaining constant. The incidence of hyperbilirubinemia (bilirubin greater than or equal to 2 mg/dL) increased from 48% to 80% (P = .02), and the mean maximal bilirubin increased from 4.67 +/- 7.27 to 8.72 +/- 8.73 mg/dL (P = .04), when CyA/MTX was used in place of CyA/MP for GVHD prophylaxis. In addition, the incidence of veno-occlusive disease (VOD) increased from 18% to 70% (P = .0001), and death caused by VOD increased from 4.5% to 25% (P = .02). Survival was not significantly different for the two groups because of a higher non-VOD death rate in patients receiving CyA/MP for GVHD prophylaxis (P = .77). We suggest caution when using Bu4Cy2 in combination with CyA/MTX for GVHD prophylaxis.

Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease

1996 ◽  
Vol 6 (3) ◽  
pp. 261-271 ◽  
Author(s):  
J. Chapman ◽  
R. D. Finney ◽  
K. Forman ◽  
P. Kelsey ◽  
S. M. Knowles ◽  
...  
Keyword(s):  
Gamma Irradiation ◽  
Graft Versus Host Disease ◽  
Blood Components ◽  
Host Disease ◽  
Graft Versus Host

Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report

2017 ◽  
Vol 58 (11) ◽  
pp. 2770-2771 ◽  
Author(s):  
Federica Cocito ◽  
Silvia Mangiacavalli ◽  
Paolo Bernasconi ◽  
Anna A. Colombo ◽  
Daniela Caldera ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplant ◽  
Host Disease ◽  
Graft Versus Host
Sign in / Sign up

Export Citation Format

Share Document